During the last session, Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares were 0.32 million, with the beta value of the company hitting 2.70. At the end of the trading day, the stock’s price was $34.07, reflecting an intraday gain of 2.90% or $0.96. The 52-week high for the ALGS share is $35.30, that puts it down -3.61 from that peak though still a striking 80.16% gain since the share price plummeted to a 52-week low of $6.76. The company’s market capitalization is $122.24M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 323.46K shares over the past three months.
Aligos Therapeutics Inc (ALGS) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.00. ALGS has a Sell rating from 2 analyst(s) out of 9 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.67.
Aligos Therapeutics Inc (NASDAQ:ALGS) trade information
Aligos Therapeutics Inc (ALGS) registered a 2.90% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.90% in intraday trading to $34.07, hitting a weekly high. The stock’s 5-day price performance is 18.84%, and it has moved by 74.00% in 30 days. Based on these gigs, the overall price performance for the year is 132.96%. The short interest in Aligos Therapeutics Inc (NASDAQ:ALGS) is 0.28 million shares and it means that shorts have 0.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies a decrease of -1035.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, ALGS is trading at a premium of 91.19% off the target high and 91.19% off the low.
Aligos Therapeutics Inc (ALGS) estimates and forecasts
Statistics show that Aligos Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Aligos Therapeutics Inc (ALGS) shares have gone up 172.56% during the last six months, with a year-to-date growth rate more than the industry average at 69.53% against 17.10. In the rating firms’ projections, revenue will decrease -59.91% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 433.33k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 333.33k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.01M and 986k respectively. In this case, analysts expect current quarter sales to shrink by -78.43% and then drop by -66.19% in the coming quarter.
While earnings are projected to return 70.31% in 2024.
ALGS Dividends
Aligos Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aligos Therapeutics Inc (NASDAQ:ALGS)’s Major holders
Aligos Therapeutics Inc insiders own 17.80% of total outstanding shares while institutional holders control 48.86%, with the float percentage being 59.44%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 7.26 million shares (or 4.6471% of all shares), a total value of $2.54 million in shares.
The next largest institutional holding, with 6.39 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 4.0919% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.24 million.
Also, the Mutual Funds coming in first place with the largest holdings of Aligos Therapeutics Inc (ALGS) shares are Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 52.8 shares. This amounts to just over 1.47 percent of the company’s overall shares, with a $1.8 million market value. The same data shows that the other fund manager holds slightly less at 12.39, or about 0.35% of the stock, which is worth about $0.42 million.
